2024
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review)
Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). International Journal Of Molecular Medicine 2024, 55: 6. PMID: 39450552, PMCID: PMC11537269, DOI: 10.3892/ijmm.2024.5447.Peer-Reviewed Original ResearchConceptsDisease-free survivalBreast cancerPrecision medicine approachAvailability of high-throughput sequencingPrecision oncologyTherapeutic optionsDriver mutationsDisease-free survival of patientsCancer driver gene identificationDriver gene identificationMedicine approachHigh-throughput sequencingSurvival of patientsTargeted therapeutic optionsFraction of patientsCancer driver mutationsTargeted therapeutic approachesBreast cancer treatmentIdentification of driver mutationsBreast cancer mutationsModern era of medicineCancer-specific biomarkersGene identificationCancer DatabaseCancer mutations
2021
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics
Ding R, Chen P, Rajendran B, Lyu X, Wang H, Bao J, Zeng J, Hao W, Sun H, Wong A, Valecha M, Yang E, Su S, Choi T, Liu S, Chan K, Yang L, Wu J, Miao K, Chen Q, Shim J, Xu X, Deng C. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nature Communications 2021, 12: 3046. PMID: 34031426, PMCID: PMC8144567, DOI: 10.1038/s41467-021-23379-3.Peer-Reviewed Original ResearchConceptsSarcomatoid carcinomaEpithelial-mesenchymal transitionNasopharyngeal carcinomaCarcinoma subtypesNeck cancer typesPatient-derived organoidCRT regimensDistinct molecular featuresMalignant headHigh morbidityTreatment regimensTherapeutic responseEC subtypesPathogenic mechanismsDrug responsivenessEGFR inhibitorsNPC subtypesCancer typesSubtypesCarcinomaPrecision oncologyDrug testsMolecular landscapeRegimensMicrotubule inhibitors